Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers

NCT02833389 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02833389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2016
Completion date
November 12, 2018
Enrollment
72 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic diabetic foot ulcers